Literature DB >> 26085138

Discovery of another anti-HIV protein in the search for the CD8+ cell anti-HIV Factor.

Jay A Levy1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26085138      PMCID: PMC4491768          DOI: 10.1073/pnas.1509324112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  37 in total

1.  Differential gene expression in CD8+ cells exhibiting noncytotoxic anti-HIV activity.

Authors:  Leyla S Diaz; Mars R Stone; Carl E Mackewicz; Jay A Levy
Journal:  Virology       Date:  2003-07-05       Impact factor: 3.616

2.  alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors.

Authors:  Carl E Mackewicz; Jun Yuan; Patti Tran; Leyla Diaz; Elizabeth Mack; Michael E Selsted; Jay A Levy
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

Review 3.  Control of HIV-1 infection by soluble factors of the immune response.

Authors:  Anthony L DeVico; Robert C Gallo
Journal:  Nat Rev Microbiol       Date:  2004-05       Impact factor: 60.633

4.  Differential gene expression in CD8(+) cells from HIV-1-infected subjects showing suppression of HIV replication.

Authors:  Beatriz Martinez-Mariño; Hillary Foster; Yanling Hao; Jay A Levy
Journal:  Virology       Date:  2007-01-22       Impact factor: 3.616

5.  HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family.

Authors:  Ralf Geiben-Lynn; Mischo Kursar; Nancy V Brown; Marylyn M Addo; Hungyi Shau; Judy Lieberman; Andrew D Luster; Bruce D Walker
Journal:  J Biol Chem       Date:  2002-11-05       Impact factor: 5.157

6.  Cellular uptake of the tat protein from human immunodeficiency virus.

Authors:  A D Frankel; C O Pabo
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

7.  Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.

Authors:  M Kuppuswamy; T Subramanian; A Srinivasan; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

8.  A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication.

Authors:  C M Walker; J A Levy
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

9.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

Review 10.  The search for the CD8+ cell anti-HIV factor (CAF).

Authors:  Jay A Levy
Journal:  Trends Immunol       Date:  2003-12       Impact factor: 16.687

View more
  5 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Analysis of the CD8+ T cell anti-HIV activity in heterologous cell co-cultures reveals the benefit of multiple HLA class I matches.

Authors:  M Scott Killian; Fernando Teque; Ramu Sudhagoni
Journal:  Immunogenetics       Date:  2017-07-22       Impact factor: 2.846

3.  Canonical Wnts Mediate CD8+ T Cell Noncytolytic Anti-HIV-1 Activity and Correlate with HIV-1 Clinical Status.

Authors:  Jennillee Wallace; Srinivas D Narasipura; Beverly E Sha; Audrey L French; Lena Al-Harthi
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

4.  Suppression of HIV Replication by CD8(+) Regulatory T-Cells in Elite Controllers.

Authors:  Wei Lu; Song Chen; Chunhui Lai; Mingyue Lai; Hua Fang; Hong Dao; Jun Kang; Jianhua Fan; Weizhong Guo; Linchun Fu; Jean-Marie Andrieu
Journal:  Front Immunol       Date:  2016-04-18       Impact factor: 7.561

5.  Notwithstanding Circumstantial Alibis, Cytotoxic T Cells Can Be Major Killers of HIV-1-Infected Cells.

Authors:  Saikrishna Gadhamsetty; Tim Coorens; Rob J de Boer
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.